Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Note
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by Marky1on Aug 09, 2021 2:32pm
216 Views
Post# 33672876

RE:Note

RE:Note Though I do not post here or ceo any longer...Just want to say to Layth....You are 100% correct! This stock, I believe will fully recover, May take 6 months but it will get back up.
The science is too powerful to deny.
55,000 pages of data on 346 is real.
Dr. Stauffer and a foot in the FDA is an amazing asset.
Dr. Haut know who to talk to at Bayer, has their phone numbers, knows how to draw up a contract..I'm confident that at this moment in time he is inking some sort of agreement with Bayer.
We have 15 years of hard work by our world renowned and respected founder, Dr. Wallace.
This is a great time to average down, folks, take advantage of it.
insiders are buying...u should too!

best of luck to all the intelligent longs here!
Peace out
JM
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities